title: A globin fragment, LVV-hemorphin-7, induces [3H]thymidine incorporation in a neuronal cell line via the AT4 receptor.
abstract: The AT4 receptor was characterized initially as a specific binding site for angiotensin IV, a C-terminal fragment of the vasoactive peptide angiotensin II. Recently, we found that LVV-hemorphin-7, a fragment of beta globin, is an abundant peptide in the brain and binds to the AT4 receptor with high affinity and specificity. In the neuroblastoma/glioma hybrid cell line, NG108-15, LVV-hemorphin-7 and angiotensin IV competed for 125I-angiotensin IV binding in a biphasic fashion with IC50 values of 1.2 x 10(-10) and 1.1 x 10(-9) M for the high-affinity site, respectively, and 6.7 x 10(-8) and 1.5 x 10(-8) M for the low-affinity site, respectively. Both peptides were internalized rapidly by the cells. However, LVV-hemorphin-7, but not angiotensin IV, elicited a 1.8-fold increase in DNA synthesis in a dose-dependent manner. Furthermore, co-incubation of the cells with an excess of angiotensin IV (10(-6) M) inhibited LVV-hemorphin-7-stimulated DNA synthesis. Therefore, whereas LVV-hemorphin-7 and angiotensin IV were capable of binding to the AT4 receptor, only LVV-hemorphin-7 elicited [3H]thymidine incorporation in NG108-15 cells. In contrast, angiotensin IV behaved as an antagonist. The current finding suggests that LVV-hemorphin-7 is a functional peptide in the central nervous system and in view of its abundance in neural tissue, compared with angiotensin IV, may be of significant physiological importance.
authors.affiliation: Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Parkville, Victoria, Australia.
authors.forename: I
authors.initials: I
authors.lastname: Moeller
authors.forename: A L
authors.initials: AL
authors.lastname: Albiston
authors.forename: R A
authors.initials: RA
authors.lastname: Lew
authors.forename: F A
authors.initials: FA
authors.lastname: Mendelsohn
authors.forename: S Y
authors.initials: SY
authors.lastname: Chai
mesh_terms: D000804:Angiotensin II / Q000031:analogs & derivatives / Q000378:metabolism; D001667:Binding, Competitive; D004247:DNA / Q000096:biosynthesis*; D005910:Glioma; D006454:Hemoglobins / Q000378:metabolism / Q000494:pharmacology*; D006822:Hybrid Cells; D019808:Losartan / Q000378:metabolism; D009447:Neuroblastoma; D009474:Neurons / Q000378:metabolism*; D010446:Peptide Fragments / Q000378:metabolism / Q000494:pharmacology*; D011945:Receptors, Angiotensin / Q000378:metabolism*; D013936:Thymidine / Q000378:metabolism; D014316:Tritium; D014407:Tumor Cells, Cultured
chemical_list: C090830:AT4 receptor; D006454:Hemoglobins; D010446:Peptide Fragments; D011945:Receptors, Angiotensin; D014316:Tritium; D000804:Angiotensin II; C012877:angiotensin II, des-Asp(1)-des-Arg(2)-Ile(5)-; C074309:LVV-hemorphin-7; D004247:DNA; D019808:Losartan; D013936:Thymidine